NCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05638295 2026-04-16
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06820463 2026-04-15
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT07172919 2026-04-09
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Phase 2 Recruiting
NCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT06714357 2025-12-17
VICTORIA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT05694936 2025-09-18
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT06575127 2024-08-28
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
Phase 2 Recruiting
NCT06314997 2024-03-18
Liquid-DRER2
Matteo's Friends
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting